Jie Huang

Jie Huang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
EWEleanor Wheeler
Eleanor Wheeler
ALAaron Leong
Aaron Leong
CLChing-Ti Liu
Ching-Ti Liu
MHMarie-France Hivert
Marie-France Hivert
RSRona Strawbridge
Rona Strawbridge
JMJames B. Meigs
James B. Meigs
Glycated hemoglobin (HbA1c) is used to diagnose type 2 diabetes (T2D) and assess glycemic control in patients with diabetes. Previous genome-wide association studies (GWAS) have identified 18 HbA1c-associated genetic variants. These variants proved to be classifiable by their likely biological action as erythrocytic (also associated with erythrocyte traits) or glycemic (associated with other glucose-related traits). In this study, we tested the hypotheses that, in a very large scale GWAS, we would identify more genetic variants associated with HbA1c and that HbA1c variants implicated in erythrocytic biology would affect the diagnostic accuracy of HbA1c. We therefore expanded the number of HbA1c-associated loci and tested the effect of genetic risk-scores comprised of erythrocytic or glycemic variants on incident diabetes prediction and on prevalent diabetes screening performance. Throughout this multiancestry study, we kept a focus on interancestry differences in HbA1c genetics performance that might influence race-ancestry differences in health outcomes. Using genome-wide association meta-analyses in up to 159,940 individuals from 82 cohorts of European, African, East Asian, and South Asian ancestry, we identified 60 common genetic variants associated with HbA1c. We classified variants as implicated in glycemic, erythrocytic, or unclassified biology and tested whether additive genetic scores of erythrocytic variants (GS-E) or glycemic variants (GS-G) were associated with higher T2D incidence in multiethnic longitudinal cohorts (N = 33,241). Nineteen glycemic and 22 erythrocytic variants were associated with HbA1c at genome-wide significance. GS-G was associated with higher T2D risk (incidence OR = 1.05, 95% CI 1.04–1.06, per HbA1c-raising allele, p = 3 × 10−29); whereas GS-E was not (OR = 1.00, 95% CI 0.99–1.01, p = 0.60). In Europeans and Asians, erythrocytic variants in aggregate had only modest effects on the diagnostic accuracy of HbA1c. Yet, in African Americans, the X-linked G6PD G202A variant (T-allele frequency 11%) was associated with an absolute decrease in HbA1c of 0.81%-units (95% CI 0.66–0.96) per allele in hemizygous men, and 0.68%-units (95% CI 0.38–0.97) in homozygous women. The G6PD variant may cause approximately 2% (N = 0.65 million, 95% CI 0.55–0.74) of African American adults with T2D to remain undiagnosed when screened with HbA1c. Limitations include the smaller sample sizes for non-European ancestries and the inability to classify approximately one-third of the variants. Further studies in large multiethnic cohorts with HbA1c, glycemic, and erythrocytic traits are required to better determine the biological action of the unclassified variants. As G6PD deficiency can be clinically silent until illness strikes, we recommend investigation of the possible benefits of screening for the G6PD genotype along with using HbA1c to diagnose T2D in populations of African ancestry or groups where G6PD deficiency is common. Screening with direct glucose measurements, or genetically-informed HbA1c diagnostic thresholds in people with G6PD deficiency, may be required to avoid missed or delayed diagnoses.

1 August 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CTCatherine Tcheandjieu
Catherine Tcheandjieu
XZXiang Zhu
Xiang Zhu
AHAustin T. Hilliard
Austin T. Hilliard
SCShoa L. Clarke
Shoa L. Clarke
Valerio NapolioniValerio Napolioni
Valerio Napolioni
MPMillion Veteran Program
Million Veteran Program

2 June 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MVMarijana Vujkovic
Marijana Vujkovic
SRShweta Ramdas
Shweta Ramdas
KLKim M. Lorenz
Kim M. Lorenz
XGXiuqing Guo
Xiuqing Guo
RDRebecca Darlay
Rebecca Darlay
KCKyong-Mi Chang
Kyong-Mi Chang

21 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
JHJie Huang
Jie Huang
JLJun Liu
Jun Liu
RTRuiyi Tian
Ruiyi Tian
Kevin LiuKevin Liu
Kevin Liu
PZPatrick Zhuang
Patrick Zhuang
XKXuejun Kong
Xuejun Kong
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with strong genetic influences. There is an increasing demand for ASD genetic testing beyond the traditionally recommended microarray and syndromic autism testing; however, the current whole genome sequencing (WGS) and whole exome sequencing (WES) methods are lacking an academic standard for WGS variant annotation, reporting, and interpretation, tailored towards patients with ASD and offer very limited interpretation for clinical significance. Using WGS data from six family trios, we demonstrate the clinical feasibility and technical implementation of an evidence-based, fully transparent bioinformatics pipeline and report framework for an ASD-focused WGS genetic report. We confirmed a portion of the key variants with Sanger sequencing and provided interpretation with consideration of patients’ clinical symptoms and detailed literature review. Furthermore, we showed that identification of the genetic contributions of ASD core symptoms and comorbidities may promote a better understanding of the ASD pathophysiology, lead to early detection of associated comorbidities, and facilitate pharmacologic intervention based on pathological pathways inferred from the genetic information. We will make the bioinformatics pipeline and interpretation framework publicly available, in an easily accessible format, after validation with a larger cohort. We hope that the present proposed protocol can serve as a starting point to invite discourse and debate to further improve approaches in WGS-based genetic consultation for patients with ASD.

25 February 2022 in Diabetes Care
Verified
Journal Article
Open access
PDF file
MWMengying Wang
Mengying Wang
JHJie Huang
Jie Huang
TWTao Wu
Tao Wu
LQLu Qi
Lu Qi
OBJECTIVE: We aimed to investigate prospective associations of pulse wave arterial stiffness index (ASI) and pulse pressure (PP) with type 2 diabetes (T2D) and assess the modifying effect of genetics. RESEARCH DESIGN AND METHODS: We included 152,611 participants free of diabetes and cardiovascular disease in the UK Biobank. All participants had ASI and blood pressure measurements collected at baseline visit. In total, 37 single nucleotide polymorphisms were used to calculate the genetic risk score (GRS) of T2D. RESULTS: During a median follow-up of 9.5 years, 3,000 participants developed T2D. Per-SD increase in ASI was associated with a 3% higher T2D risk (95% CI 2–4%). The hazard ratio (HR) (95% CI) of T2D was 1.58 (1.39–1.80) in the highest quintile group compared with the lowest quintile group of ASI. However, the association between PP and T2D was nonlinear. Compared with the lowest quintile group, the risk of T2D in higher quintile groups of PP was 0.91 (0.79–1.04), 0.98 (0.86–1.11), 1.15 (1.01–1.30), and 1.24 (1.10–1.41), respectively. Furthermore, we observed an interaction between ASI and genetic susceptibility to T2D, because the elevated HR of T2D associated with high ASI was more evident among participants with higher GRS of T2D (P interaction = 0.008), whereas the interaction between PP and GRS was nonsignificant (P interaction = 0.55). CONCLUSIONS: ASI was associated with an elevated risk of T2D in a dose-response fashion, whereas PP and T2D showed a nonlinear J-shaped association. Additionally, the association between ASI and T2D was partially strengthened by higher genetic susceptibility to T2D.

10 September 2024 in Metabolism
Verified
Journal Article
Closed access
HGHuangda Guo
Huangda Guo
SWSiyue Wang
Siyue Wang
HPHexiang Peng
Hexiang Peng
WWWeiwei Wang
Weiwei Wang
THTianjiao Hou
Tianjiao Hou
TWTao Wu
Tao Wu